Laurent Vernillet

3.0k total citations
57 papers, 2.0k citations indexed

About

Laurent Vernillet is a scholar working on Molecular Biology, Oncology and Nephrology. According to data from OpenAlex, Laurent Vernillet has authored 57 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 23 papers in Oncology and 13 papers in Nephrology. Recurrent topics in Laurent Vernillet's work include Cancer therapeutics and mechanisms (13 papers), Gout, Hyperuricemia, Uric Acid (12 papers) and Pharmacological Effects and Toxicity Studies (8 papers). Laurent Vernillet is often cited by papers focused on Cancer therapeutics and mechanisms (13 papers), Gout, Hyperuricemia, Uric Acid (12 papers) and Pharmacological Effects and Toxicity Studies (8 papers). Laurent Vernillet collaborates with scholars based in France, United States and United Kingdom. Laurent Vernillet's co-authors include Nancy Joseph‐Ridge, Reza Khosravan, Jingtao Wu, Brian Grabowski, Darcy J. Mulford, Éric Raymond, Michael D. Mayer, Valérie Boige, Marie‐Christine Haaz and William Palo and has published in prestigious journals such as Journal of Clinical Oncology, Neurology and Clinical Cancer Research.

In The Last Decade

Laurent Vernillet

57 papers receiving 1.9k citations

Peers

Countries citing papers authored by Laurent Vernillet

Since Specialization

Citations

This map shows the geographic impact of Laurent Vernillet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laurent Vernillet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laurent Vernillet more than expected).

Fields of papers citing papers by Laurent Vernillet

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laurent Vernillet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laurent Vernillet. The network helps show where Laurent Vernillet may publish in the future.

Co-authorship network of co-authors of Laurent Vernillet

This figure shows the co-authorship network connecting the top 25 collaborators of Laurent Vernillet. A scholar is included among the top collaborators of Laurent Vernillet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laurent Vernillet. Laurent Vernillet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokinetic–Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor 2012 ·Clinical Cancer Research ·Harvey Wong, Laurent Vernillet, Amy Peterson, Joseph A. Ware, Lillian Lee, Jean‐François Martini, Peiwen Yu, Congfen Li, Geoffrey Del Rosario, Edna F. Choo, Klaus P. Hoeflich, Yongchang Shi, Blake T. Aftab, (unknown), (unknown), Marcia Belvin, John Prescott	65
2	Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a non‐purine selective inhibitor of xanthine oxidase 2010 ·British Journal of Clinical Pharmacology ·Brian Grabowski, Reza Khosravan, Jingtao Wu, Laurent Vernillet, Christopher Lademacher	20
3	Metabolism and Excretion of [¹⁴C] Febuxostat, a Novel Nonpurine Selective Inhibitor of Xanthine Oxidase, in Healthy Male Subjects 2010 ·The Journal of Clinical Pharmacology ·Brian Grabowski, Reza Khosravan, Laurent Vernillet, Darcy J. Mulford	50
4	Interplay of Dissolution, Solubility, and Nonsink Permeation Determines the Oral Absorption of the Hedgehog Pathway Inhibitor GDC-0449 in Dogs: An Investigation Using Preclinical Studies and Physiologically Based Pharmacokinetic Modeling 2010 ·Drug Metabolism and Disposition ·Harvey Wong, Frank‐Peter Theil, Yong Cui, James C. Marsters, S. Cyrus Khojasteh, Laurent Vernillet, Hank La, (unknown), Hong Wang, Eric J. Morinello, Yuzhong Deng, Cornelis E. C. A. Hop	17
5	A Phase IB Trial of Intravenous INO-1001 Plus Oral Temozolomide in Subjects with Unresectable Stage-III or IV Melanoma 2009 ·Cancer Investigation ·Agop Y. Bedikian, Nicholas E. Papadopoulos, Kevin B. Kim, Wen-Jen Hwu, Jade Homsi, (unknown), (unknown), Patrick J. Rudewicz, Laurent Vernillet, Patrick Hwu	52
6	The Effect of Age and Gender on Pharmacokinetics, Pharmacodynamics, and Safety of Febuxostat, a Novel Nonpurine Selective Inhibitor of Xanthine Oxidase 2008 ·The Journal of Clinical Pharmacology ·Reza Khosravan, Michael Kukulka, Jingtao Wu, Nancy Joseph‐Ridge, Laurent Vernillet	40
7	Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects 2007 ·British Journal of Clinical Pharmacology ·Reza Khosravan, Brian Grabowski, Jingtao Wu, Nancy Joseph‐Ridge, Laurent Vernillet	67
8	Pharmacokinetics, Pharmacodynamics and Safety of Febuxostat, a Non-Purine Selective Inhibitor of Xanthine Oxidase, in a Dose Escalation Study in Healthy Subjects 2006 ·Clinical Pharmacokinetics ·Reza Khosravan, Brian Grabowski, Jingtao Wu, Nancy Joseph‐Ridge, Laurent Vernillet	84
9	Pharmacokinetic Interactions of Concomitant Administration of Febuxostat and NSAIDs 2006 ·The Journal of Clinical Pharmacology ·Reza Khosravan, Jingtao Wu, Nancy Joseph‐Ridge, Laurent Vernillet	39
10	The Effect of Mild and Moderate Hepatic Impairment on Pharmacokinetics, Pharmacodynamics, and Safety of Febuxostat, a Novel Nonpurine Selective Inhibitor of Xanthine Oxidase 2006 ·The Journal of Clinical Pharmacology ·Reza Khosravan, Brian Grabowski, Michael D. Mayer, Jingtao Wu, Nancy Joseph‐Ridge, Laurent Vernillet	62
11	Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma 2003 ·Annals of Oncology ·Éric Raymond, Michel Fabbro, Valérie Boige, Olivier Rixe, Marc Frénay, Gilles Vassal, Sandrine Faivre, (unknown), Caroline Germa, (unknown), Laurent Vernillet, Jean‐Pierre Armand	67
12	Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer 2002 ·British Journal of Cancer ·P. Vasey, Henri Roché, D. Bisset, C. Terret, Laurent Vernillet, A. Riva, (unknown), N. Azli, S.B. Kaye, Chris Twelves	3
13	Phase I dose-finding and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer 2001 ·Annals of Oncology ·Mario Campone, P. Fumoleau, Valérie Delecroix, R. Déporte-Féty, G. Perrocheau, Laurent Vernillet, (unknown), J.P. Louboutin, Marie-Christine Bissery, A. Riva, N. Azli	20
14	Phase I study of irinotecan and raltitrexed in patients with advanced astrointestinal tract adenocarcinoma 2000 ·British Journal of Cancer ·Hugo Ford, David Cunningham, Paul J. Ross, Shuan Rao, G. Wynne Aherne, T. Benepal, Timothy Price, Alison Massey, Laurent Vernillet	21
15	Sparse-data set analysis for irinotecan and SN-38 pharmacokinetics in cancer patients co-treated with cisplatin 1999 ·Anti-Cancer Drugs ·Ron H.J. Mathijssen, R J van Alphen, Maja J. De Jonge, Jaco J. Verweij, Peter de Bruijn, (unknown), Kees Nooter, Laurent Vernillet, Gerrit Stoter, Alex Sparreboom	9
16	Simultaneous determination of the lactone and carboxylate forms of the camptothecin derivative CPT-11 and its metabolite SN-38 in plasma by high-performance liquid chromatography 1998 ·Journal of Chromatography B Biomedical Sciences and Applications ·(unknown), (unknown), (unknown), Guy Montay, Laurent Vernillet, (unknown), (unknown)	46
17	A rapid reversed phase high performance liquid chromatographic method for the determination of docetaxel (Taxotere®) in human plasma using a column switching technique 1998 ·Journal of Pharmaceutical and Biomedical Analysis ·Mohammad Reza Rouini, (unknown), David J. Stewart, J. Matshela Molepo, Farshad H. Shirazi, J. Vergniol, Eva Tomiak, Fabian Delorme, Laurent Vernillet, (unknown), Rakesh Goel	41
18	Cyclosporine Disposition and Metabolite Profiles in Renal Transplant Patients Receiving a Microemulsion Formulation 1994 ·Therapeutic Drug Monitoring ·John M. Kovarik, Laurent Vernillet, Edgar A. Mueller, (unknown), Werner Niederberger, Klaus Kutz	25
19	Trials of the bronchodilator activity of the xanthine analogue SDZ MKS 492 in healthy volunteers during a methacholine challenge test 1993 ·European Journal of Clinical Pharmacology ·(unknown), (unknown), Nageeb Hassan, (unknown), Laurent Vernillet, J. Denouël, John R. Carpenter, R.C. Small	1
20	Lack of effect of isradipine on cyclosporin pharmacokinetics 1992 ·Fundamental and Clinical Pharmacology ·Laurent Vernillet, B. Bourbigot, (unknown), Olivia Le Saux, (unknown), (unknown)	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact